UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-14656 REPLIGEN CORPORATION (Exact name of registrant as specified in its charter) Delaware 04-2729386 (State or other jurisdiction of (I.R.S. Em ...

Repligen Corporation (NASDAQ:RGEN) Q4 2023 Earnings Conference Call February 21, 2024 8:30 AM ET Company Participants Sondra Newman - Global Head, IR Anthony Hunt - CEO & Director Jason Garland - CFO Conference Call Participants Daniel Leonard - UBS Matthew Larew - William Blair & Company Puneet Souda - Leerink Partners Conor McNamara - RBC Capital Markets Matthew Hewitt - Craig-Hallum Capital Justin Bowers - Deutsche Bank Paul Knight - KeyBanc Capital Markets Daniel Arias - Stifel, Nicolaus & Company Rache ...

Exhibit 99.1 Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports Fourth Quarter and Full Year 2023 Financial Results • Reports fourth quarter revenue of $156 million and full year revenue of $639 million • Continued strength in orders with fourth quarter book-to-bill ratio of 1.03 WALTHAM, Mass., February 21, 2024 — Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (cid:0) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period e nded September 30, 2023 OR (cid:0) TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to___________ Commission File Number 000-14656 REPLIGEN CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 04-27293 ...

Repligen Corporation (NASDAQ:RGEN) Q3 2023 Earnings Conference Call October 31, 2023 8:30 AM ET Company Participants Sondra Newman – Head of Investor Relations Tony Hunt – Chief Executive Officer Jason Garland – Chief Financial Officer Conference Call Participants Jacob Johnson – Stephens Conor McNamara – RBC Capital Markets Dan Arias – Stifel Puneet Souda – Leerink Partners Matt Larew – William Blair Matt Hewitt – Craig-Hallum Capital Group Tim Daley – Wells Fargo Rachel Vatnsdal – J.P. Morgan Dan Leonard ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (cid:0) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly perio d ended June 30, 2023 OR (cid:0) TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to___________ Commission File Number 000-14656 REPLIGEN CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 04-2729386 (S ...

Repligen Corporation (NASDAQ:RGEN) Q2 2023 Earnings Conference Call August 2, 2023 8:30 AM ET Company Participants Sondra Newman - Global Head of Investor Relations Tony Hunt - President and Chief Executive Officer Jon Snodgres - Chief Financial Officer Conference Call Participants Puneet Souda - Leerink Partners Jacob Johnson - Stephens Dan Arias - Stifel Matt Larew - William Blair Rachel Vatnsdal - J.P. Morgan Paul Knight - KeyBanc Capital Markets Conor McNamara - RBC Capital Markets Matt Hewitt - Craig H ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (cid:0) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR (cid:0) TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to___________ Commission File Number 000-14656 REPLIGEN CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 04-2729386 (S ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-14656 REPLIGEN CORPORATION (Exact name of registrant as specified in its charter) Delaware 04-2729386 (State or other jurisdiction of (I.R.S. Em ...